Latest Share Based Payments News

archTIS Limited reported a 38% revenue decline and an 11.8% rise in net loss for FY2025, yet achieved positive operating cash flow and secured $7.5 million in new capital to accelerate international expansion.

Harvest Technology Group reported a reduced net loss of $7.06 million for FY2025 amid restructuring and new funding, while focusing on its remote communications technology segment and launching Project NEON.

Mach7 Technologies Limited reported a 16% revenue increase to AUD 33.8 million for FY25, alongside a 22% reduction in net loss, driven by a strategic shift to subscription-based sales and disciplined cost management.

Matrix Composites & Engineering Ltd posted a 12.1% revenue decline to $74.77 million for FY25, reporting a net loss of $2.2 million as subdued drilling buoyancy markets weighed on results despite strong growth in subsea buoyancy products.

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

Iondrive Ltd reported a 94.7% surge in revenue to $1.71 million for FY2025, driven by R&D tax incentives and other income, yet still recorded a net loss of $4.62 million amid high expenses. The company also expanded its footprint in Europe by acquiring a German entity.

Askari Metals is gearing up for a pivotal shareholder meeting to approve its Ethiopian gold and copper acquisition, while restructuring debt and expanding European investor outreach.

Asset Vision Co Limited reported a 22.9% increase in revenue to $5.03 million for FY2025, alongside a widening net loss of $385,797. The company’s Annual Recurring Revenue surged 28%, supported by new contracts and product innovation.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.